The clinical implications of reduced viral fitness

被引：6

作者：

Barbour J.D. ^{[1
]}

Grant R.M. ^{[1
]}

机构：

[1] Gladstone Inst. Virology/Immunology, San Francisco, CA 94141

来源：

Current Infectious Disease Reports | 2004年 / 6卷 / 2期

关键词：

Virologic Failure; Replication Capacity; Oseltamivir Carboxylate; Viral Fitness; Viral Replication Capacity;

D O I：

10.1007/s11908-996-0012-x

中图分类号：

学科分类号：

摘要：

Viral fitness, defined as the extent of viral adaptation to the host environment, arises from tissue tropism, immune system evasion, drug resistance, and viral replication capacity. The fitness of wild-type and drug-resistant HIV-1 varies widely, associating with plasma viremia, CD4+ T-cell count, and clinical progression. HIV-1 fitness may be measured in competitive culture assays, single cycle assays, or single cycle assays based on a subgenomic fragment of HIV-1, which has been standardized as the replication capacity assay (pol RC). During virologic failure of antiretroviral therapy, CD4 T-cell counts remain elevated while pot RC declines and remains durably lower because of drug-selected changes in the gag and pol genes. CD4 T-cell sparing also is observed among patients without evidence of drug resistance who carry a low pol RC virus. Reduced HIV-1 replication capacity and virulence may occur because of drug resistance or viral escape from host immune responses. Copyright © 2004 by Current Science Inc.

引用

页码：151 / 158

页数：7

共 58 条

[1]

Mellors J.W., Munoz A., Giorgi J.V., Et al., Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection, Ann. Intern. Med., 126, pp. 946-954, (1997)

[2]

Carrington M., O'Brien S.J., The influence of HLA genotype on AIDS, Annu. Rev. Med., 54, pp. 535-551, (2003)

[3]

Eron J.J., Benoit S.L., Jemsek L., Et al., Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter, N. Engl. J. Med., 333, pp. 1662-1669, (1995)

[4]

Ledergerber B., Egger M., Opravil M., Et al., Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study, Lancet, 353, pp. 863-868, (1999)

[5]

Korber B., Muldoon M., Theiler J., Et al., Timing the ancestor of the HIV-1 pandemic strains, Science, 288, pp. 1789-1796, (2000)

[6]

Hahn B.H., Shaw G.M., De Cock K.M., Sharp P.M., AIDS as a zoonosis: Scientific and public health implications, Science, 287, pp. 607-614, (2000)

[7]

Peeters M., Fransen K., Delaporte E., Et al., Isolation and characterization of a new chimpanzee lentivirus (simian immunodeficiency virus isolate cpz-ant) from a wild-captured chimpanzee, AIDS, 6, pp. 447-451, (1992)

[8]

Carr J., Ives J., Kelly L., Et al., Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo, Antiviral Res., 54, pp. 79-88, (2002)

[9]

Shankar N., Baghdayan A.S., Gilmore M.S., Modulation of virulence within a pathogenicity island in vancomycin-resistant Enterococcus faecalis, Nature, 417, pp. 746-750, (2002)

[10]

Baba T., Takeuchi F., Kuroda M., Et al., Genome and virulence determinants of high virulence community-acquired MRSA, Lancet, 359, pp. 1819-1827, (2002)

← 1 2 3 4 5 6 →